Glenmark Generics Inc has been granted final approval for their ANDA from the United States Food and Drug Administration for Levocetirizine Dihydrochloride 5mg tablets
Pharma major Glenmark Pharmaceuticals Ltd said its US arm has received final approval from the US health regulator to market generic Levocetirizine Dihydrochloride tablets used for treating allergies in the American market.
"Glenmark Generics Inc has been granted final approval for their Abbreviated New Drug Application (ANDA) from the United States Food and Drug Administration for Levocetirizine Dihydrochloride 5mg tablets," Glenmark said in a filing to the Bombay Stock Exchange (BSE).
The tablets are generic version of UCB Inc's Xyzal tablets, it added.
Quoting IMS Health, Glenmark said: "Total US sales as reported by IMS Health for the 12-month period ending December 2010 were approximately $231 million."
Levocetirizine Dihydrochloride tablets are used for relief of symptoms associated with allergic rhinitis, which is an allergic inflammation of the nasal airways.
On Friday, Glenmark ended 0.60% down at Rs280.40 on the BSE, while the benchmark Sensex gained 0.39% to 17,700.91.
The record date for the UTI–Master Value Fund dividend is 1 March 2011
UTI-Master Value Fund declares tax-free dividend of 10% (Re1 per unit on face value of Rs10). The record date for the dividend is 1 March 2011.
The NAV per unit as on 23 February 2011 was Rs22.77 under the dividend option.
The scheme has declared dividend at regular intervals.
Samridhi Plus will be available for sale for a maximum period of three months from date of launch
Life Insurance Corporation of India (LIC) has launched a new plan 'Samridhi Plus', which is a guaranteed net asset value (NAV) plan on the new unit linked insurance plan (ULIP) platform. This plan will be available for sale for a maximum period of three months from date of launch.
In this product there is a guarantee of the highest NAV recorded on a daily basis, in the first 100 months of the policy, subject to a minimum of Rs10, or the NAV as applicable on the date of maturity, whichever is higher. The guarantee will be applicable only for units available in the policyholder's fund at the end of the policy term.
In case of death of the life assured within the policy term, when the cover is in full force, the nominee shall get higher of the sum assured under the basic plan and the policyholder's fund value.
Accident benefit would be equal to the life cover up to a maximum of Rs50 lakh, subject to certain conditions. The policy term is fixed for 10 years.
The minimum age at entry under this plan is 8 years while the maximum age is 65 years. The minimum premium ranges from Rs1,500 (Monthly-ECS) to Rs30,000 (single premium) depending on the mode of payment while the maximum is Rs1 lakh per annum under any mode for the 5 years premium paying term. There is no maximum limit for the single premium.
Two partial withdrawals per year are allowed after the fifth policy anniversary.
The sum assured under the 5 years premium paying term policies for age at entry below 45 years ranges from 10 times the annualized premium to 20 times the annualized premium. For age at entry 45 years and above the sum assured ranges from 7 times the annualized premium to 10 times the annualized premium. In case of single premium policies, for age at entry below 45 years, the minimum sum assured is 1.25 times the single premium while it is 1.10 times the single premium for age at entry 45 years and above. The maximum sum assured under single premium policies is 5 times the single premium if the age at entry is upto 55 years and it 1.25 times the single premium, if age at entry is 56 to 65 years.